This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gross, A. W.
Right arrow Articles by Ren, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, A. W.
Right arrow Articles by Ren, R.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, October 1999, p. 6918-6928, Vol. 19, No. 10
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Bcr-Abl with an SH3 Deletion Retains the Ability To Induce a Myeloproliferative Disease in Mice, yet c-Abl Activated by an SH3 Deletion Induces Only Lymphoid Malignancy

Alec W. Gross,1 Xiaowu Zhang,2 and Ruibao Ren1,*

Rosenstiel Basic Medical Sciences Research Center, Department of Biology,1 and Department of Biochemistry,2 Brandeis University, Waltham, Massachusetts 02454-9110

Received 9 April 1999/Returned for modification 17 May 1999/Accepted 19 July 1999

The bcr-abl oncogene plays a critical role in the pathogenesis of chronic myelogenous leukemia (CML). The fusion of Bcr sequences to Abl constitutively activates the Abl protein tyrosine kinase. We have recently shown that expression of Bcr-Abl in bone marrow cells by retroviral transduction efficiently induces in mice a myeloproliferative disease resembling human CML and that Abl kinase activity is essential for Bcr-Abl to induce a CML-like myeloproliferative disease. However, it is not known if activation of the Abl kinase alone is sufficient to induce a myeloproliferative disease. In this study, we examined the role of the Abl SH3 domain of Bcr-Abl in induction of myeloproliferative disease and tested whether c-Abl activated by SH3 deletion can induce a CML-like disease. We found that Bcr-Abl with an Abl SH3 deletion still induced a CML-like disease in mice. In contrast, c-Abl activated by SH3 deletion induced only lymphoid malignancies in mice and did not stimulate the growth of myeloid colonies from 5-fluorouracil-treated bone marrow cells in vitro. These results indicate that Bcr sequences in Bcr-Abl play additional roles in inducing myeloproliferative disease beyond simply activating the Abl kinase domain and that functions of the Abl SH3 domain are either not required or redundant in Bcr-Abl-induced myeloproliferative disease. The results also suggest that the type of hematological neoplasm induced by an abl oncogene is influenced not only by what type of hematopoietic cells the oncogene is targeted into but also by the intrinsic oncogenic properties of the particular abl oncogene. In addition, we found that Delta SH3 c-Abl induced less activation of Akt and STAT5 than did Bcr-Abl, suggesting that activation of these pathways plays a critical role in inducing a CML-like disease.

* Corresponding author. Mailing address: Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, MA 02454-9110. Phone: (781) 736-2486. Fax: (781) 736-2405. E-mail: ren{at}hydra.rose.brandeis.edu.

Molecular and Cellular Biology, October 1999, p. 6918-6928, Vol. 19, No. 10
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Acquaviva, J., Chen, X., Ren, R. (2008). IRF-4 functions as a tumor suppressor in early B-cell development. Blood 112: 3798-3806 [Abstract] [Full Text]  
  • Zhang, S.-J., Ma, L.-Y., Huang, Q.-H., Li, G., Gu, B.-W., Gao, X.-D., Shi, J.-Y., Wang, Y.-Y., Gao, L., Cai, X., Ren, R.-B., Zhu, J., Chen, Z., Chen, S.-J. (2008). Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 105: 2076-2081 [Abstract] [Full Text]  
  • Parikh, C., Subrahmanyam, R., Ren, R. (2007). Oncogenic NRAS, KRAS, and HRAS Exhibit Different Leukemogenic Potentials in Mice. Cancer Res. 67: 7139-7146 [Abstract] [Full Text]  
  • Shackelford, D., Kenific, C., Blusztajn, A., Waxman, S., Ren, R. (2006). Targeted Degradation of the AML1/MDS1/EVI1 Oncoprotein by Arsenic Trioxide. Cancer Res. 66: 11360-11369 [Abstract] [Full Text]  
  • Parikh, C., Subrahmanyam, R., Ren, R. (2006). Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 108: 2349-2357 [Abstract] [Full Text]  
  • Million, R. P., Harakawa, N., Roumiantsev, S., Varticovski, L., Van Etten, R. A. (2004). A Direct Binding Site for Grb2 Contributes to Transformation and Leukemogenesis by the Tel-Abl (ETV6-Abl) Tyrosine Kinase. Mol. Cell. Biol. 24: 4685-4695 [Abstract] [Full Text]  
  • Matte, C. C., Cormier, J., Anderson, B. E., Athanasiadis, I., Liu, J., Emerson, S. G., Pear, W., Shlomchik, W. D. (2004). Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. Blood 103: 4353-4361 [Abstract] [Full Text]  
  • Jiang, X., Stuible, M., Chalandon, Y., Li, A., Chan, W. Y., Eisterer, W., Krystal, G., Eaves, A., Eaves, C. (2003). Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. Blood 102: 2976-2984 [Abstract] [Full Text]  
  • Li, S., Gillessen, S., Tomasson, M. H., Dranoff, G., Gilliland, D. G., Van Etten, R. A. (2001). Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 97: 1442-1450 [Abstract] [Full Text]  
  • Zhang, X., Subrahmanyam, R., Wong, R., Gross, A. W., Ren, R. (2001). The NH2-Terminal Coiled-Coil Domain and Tyrosine 177 Play Important Roles in Induction of a Myeloproliferative Disease in Mice by Bcr-Abl. Mol. Cell. Biol. 21: 840-853 [Abstract] [Full Text]  
  • Zhang, X., Wong, R., Hao, S. X., Pear, W. S., Ren, R. (2001). The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood 97: 277-287 [Abstract] [Full Text]  
  • Di Bacco, A., Keeshan, K., McKenna, S. L., Cotter, T. G. (2000). Molecular Abnormalities in Chronic Myeloid Leukemia: Deregulation of Cell Growth and Apoptosis. The Oncologist 5: 405-415 [Abstract] [Full Text]  
  • Million, R. P., Van Etten, R. A. (2000). The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 96: 664-670 [Abstract] [Full Text]  
  • Quackenbush, R. C., Reuther, G. W., Miller, J. P., Courtney, K. D., Pear, W. S., Pendergast, A. M. (2000). Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases. Blood 95: 2913-2921 [Abstract] [Full Text]  
  • Hao, S. X., Ren, R. (2000). Expression of Interferon Consensus Sequence Binding Protein (ICSBP) Is Downregulated in Bcr-Abl-Induced Murine Chronic Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP Inhibits Bcr-Abl-Induced Myeloproliferative Disorder. Mol. Cell. Biol. 20: 1149-1161 [Abstract] [Full Text]  
  • Dai, Z., Kerzic, P., Schroeder, W. G., McNiece, I. K. (2001). Deletion of the Src Homology 3 Domain and C-terminal Proline-rich Sequences in Bcr-Abl Prevents Abl Interactor 2 Degradation and Spontaneous Cell Migration and Impairs Leukemogenesis. J. Biol. Chem. 276: 28954-28960 [Abstract] [Full Text]  
  • Cuenco, G. M., Nucifora, G., Ren, R. (2000). Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: A model for human AML. Proc. Natl. Acad. Sci. USA 97: 1760-1765 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»